undamentalytics Newsletter
Sign in

Aurinia Pharmaceuticals Inc. (AUPH) stock

Add to watchlist

Add holding +

NASDAQ: AUPH Nasdaq Biotechnology Next results ~January 26, 2027

Aurinia Pharmaceuticals Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: data-quality checks not passed.

Price vs value

Under review: data-quality checks not passed. We'll show the comparison once resolved.

Aurinia Pharmaceuticals Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders1 buying, 1 selling11 purchases and 2 sales by directors and officers, last 12 monthsInsider trades
  • Funds149 adding, 104 cuttingOf 45 active managers that changed their stake, 21 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Aurinia Pharmaceuticals files

10-Q filed October 30: Aurinia Pharmaceuticals

Aurinia Pharmaceuticals currently generates little or no product revenue. Over the twelve months to September 2026, the company used $64m of cash, a level of spending that continues to outpace any top-line contribution. This pattern is not unusual for firms still working to turn their offerings into sales, where cash outflows often precede revenue generation. The scale of this usage points to continued reliance on existing resources or future funding to sustain operations. Set against the lack of meaningful sales, the cash burn highlights the central financial challenge facing Aurinia at this stage. How the company manages the gap between spending and revenue will remain a key factor in assessing its financial position going forward.

Our model value for Aurinia Pharmaceuticals is under review, so past values are not shown until it is resolved.

Source: 10-Q filed October 30, 2026 on SEC EDGAR · Financials · Valuation

Earlier notes (1)

Where Aurinia Pharmaceuticals stands after its latest 10-Q

Revenue for the twelve months to September 2026 was $322m, up 21.0% on a year earlier, faster than the 19.8% growth a quarter earlier. Free-cash-flow margin rose to 49.0% from 37.9% a year earlier. Operating margin widened to 48.6% from 26.3%. The diluted share count is down 4.1% on a year earlier, which lifts each remaining share. It passes 3 of our 3 financial-health checks.

10-Q on SEC EDGAR

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~January 26, 2027 (estimated)

Aurinia Pharmaceuticals Inc.'s trailing-twelve-month revenue grew 21.0% year on year, with a free-cash-flow margin of 49.0%.

Our discounted-cash-flow model values the business at ~$28 per share in the base case (~$21–$36 across growth scenarios) — model values under stated assumptions, not a price target.

Current signal Free cash flow diverging from earnings: TTM free cash flow grew 56.8% while net income grew 303.7%: a 247pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 21.0% over the last 12 months.
  • High operating margin. 48.6% of revenue is left as operating profit.
  • Margins widening. Operating margin is up 22.3 points on a year ago.
  • Strong cash generation. 49.0% of revenue turned into free cash flow.
  • Shrinking share count. Diluted shares fell 4.1% in a year, so each share owns more of the business.

Things to watch

  • Weak cash conversion. Free cash flow was 50% of net income over the last 12 months.

Latest results: FY2026 Q3

Filed October 30, 2026
Earnings per share
$0.23 against an average estimate of $0.22: beat by 4.6%
Revenue
$84m, up 13.9% on a year earlier
Share reaction
-6.2% in the first session after the results on October 30, 2026, against -2.2% for the S&P 500
Guidance given
total Revenue $325m to $330m (2026); net Product Sales $310m to $315m (2026)
Next report
October 30, 2026; average EPS estimate $0.21

Aurinia Pharmaceuticals' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-3.1%
  • 1 week-5.3%
  • 1 month+2.0%
  • This year+1.2%
  • 1 year+22.6%
  • 5 years-46.9%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$322M
Operating margin
48.6%
Net margin
97.7%
EPS (TTM, diluted)
$2.31

Growth

Revenue growth
+21.0%
Change in growth rate
+1.3 pts
Share count change
−4.1%

Cash

Free cash flow (TTM)
$158M
FCF margin
49.0%
Stock pay % of revenue
4.6%

Earnings

Last results
October 30, 2026
Next results (est.)
January 26, 2027

News & updates

Updated November 1, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Results
  2. Guidance
  3. Announcement
  4. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Aurinia Pharmaceuticals Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: data-quality checks not passed.

The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.

Valuation models

We value Aurinia Pharmaceuticals Inc. as an operating company, with every model that fits that kind of business. Cost of equity 8.9%: the 10-year Treasury yield (4.9%) plus a beta of 0.88 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Cash-flow model (DCF) Free cash flow to the firm (after stock pay, with after-tax interest added back), grown then faded to 2.5%, discounted at 8.5% as the firm rate, less debt and other claims. — Does not apply: This model is withheld pending its input or assumption review.
Forward price-to-earnings vs peers Next year's consensus earnings per share times peers' typical (harmonic-mean) forward price-to-earnings. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$14 ~$13–$28 Included
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. ~$2.6 ~$1.7–$4.3 Left out: out of range vs price (0.16x)
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. ~$1.7 ~$1.5–$2.1 Left out: out of range vs price (0.11x)
Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. — Combined value withheld. Review the individual models and their assumptions.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Aurinia Pharmaceuticals Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 2016201720182019202020212022202320242025Now
Share price$2.10$4.53$6.82$20.26$13.83$22.87$4.32$8.99$8.98$15.95$16.14
Market value$74m$348m$578m$1.9bn$1.6bn$3.0bn$613m$1.3bn$1.3bn$2.2bn$2.2bn
+ Net debt (− = net cash)−$40m−$166m−$118m−$306m−$272m−$232m−$94m−$49m−$83m−$80m−$46m
Enterprise value$34m$183m$460m$1.6bn$1.4bn$2.7bn$519m$1.2bn$1.2bn$2.1bn$2.2bn
Multiples
Price / sales n/mn/mn/mn/m32.7x64.9x4.6x7.3x5.6x7.8x6.8x
Price / earnings ————————n/m7.7x7.0x
Price / free cash flow ———————————
EV / EBITDA ————————83.3x17.1x12.2x

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

32 /100

Weak moat

How hard Aurinia Pharmaceuticals's competitive advantage looks for rivals to wear away, judged from 7 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -9.0% of total assets over 6 years.

  • Pricing power 18 / 20

    Gross margin has been a median 92.1%, moving by 4.2 percentage points (standard deviation) across 6 years.

  • Durability 10 / 20

    Operating margin has been a median -56.7%; its worst year was -112033.3%.

  • Cash conversion 5 / 20

    Free cash flow was positive in 3 of 6 years, at a median -11.9% of revenue.

  • Discipline 5 / 20

    The diluted share count rose 6.6% over five years; stock-based pay has been a median 20.5% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (37 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current $0.95 −54% $330m +17%
Next $1.17 +23% $388m +18%

Next year's EPS estimate has moved +5.5% in 90 days, across 5 analysts.

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −0.2% on 90 days ago. In the last 30 days, 1 analyst raised Aurinia Pharmaceuticals Inc.'s forecast and 2 cut it.

Consensus EPS forecast Aurinia Pharmaceuticals Inc., last 90 days
$0.90 $1.00 $1.10 $1.20 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: $0.95 Current fiscal year, 60 days ago: $0.94 Current fiscal year, 30 days ago: $0.94 Current fiscal year, 7 days ago: $0.94 Current fiscal year, Now: $0.95 $0.95 Next fiscal year, 90 days ago: $1.11 Next fiscal year, 60 days ago: $1.07 Next fiscal year, 30 days ago: $1.07 Next fiscal year, 7 days ago: $1.07 Next fiscal year, Now: $1.17 $1.17

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago $0.95$1.11
60 days ago $0.94$1.07
30 days ago $0.94$1.07
7 days ago $0.94$1.07
Now $0.95$1.17

Earnings against estimates

Quarter toEstimateActualSurprise
Sept 2026 $0.22 $0.23 +4.6%
Jun 2026 $0.24 $0.28 +16.7%
Mar 2026 $0.20 $0.25 +26.6%
Dec 2025 $0.22 $1.53 +606.1%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, October 30, 2026
  • Total Revenue 2026 $325m to $330m Raised
    “Aurinia is increasing its total revenue guidance for 2026 from a range of $315 million to $325 million to a range of $325 million to $330 million.” source
  • Net Product Sales · LUPKYNIS 2026 $310m to $315m Narrowed
    “Aurinia is narrowing its net product sales guidance for 2026 from a range of $305 million to $315 million to a range of $310 million to $315 million.” source

Figures and quotations are management's, copied from the company's own press release (SEC 8-K exhibit) and checked word for word against it. Forward-looking statements are the company's expectations, not ours and not advice; guidance can change or be missed.

Analyst recommendations

7 analysts, Oct 2026
Buy571%
Hold229%
Sell00%

Monthly trend

  1. Oct 2026527
  2. Sep 2026527
  3. Aug 2026437

Counts of recommendations published by analysts covering Aurinia Pharmaceuticals Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
6.4%
of tradable shares
Days to cover
8.95
at average volume
Short interest, 1 month
−9%
to October 15, 2026
Held by institutions
61%
of shares
Held by insiders
6.8%
of shares
Employees
128
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months +22.6%

$13.17 on October 31, 2025 to $16.14

ThenNowEffect
Revenue (last 12 months) $260m $312m +19.8%
Net margin 23.3% 100.8% +332.6%
P/E multiple 31.4x 7.0x −77.7%
Share count 144m 136m +5.9%

Biggest factor: p/e multiple.

Last 3 years +96.1%

$8.23 on November 3, 2023 to $16.14

ThenNowEffect
Revenue (last 12 months) $160m $312m +94.5%
P/S multiple 7.3x 7.1x −3.5%
Share count 142m 136m +4.5%

Biggest factor: revenue. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
AUPH+65%−81%+108%−0%+78%+1%
Industry peers (median)−36%−56%−18%−29%−5%−27%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
AUPH67%33%67%67%58%55%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
AUPH−47%−82%−42%−48%−20%−22%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 88% from October 29, 2021 to December 27, 2022. Getting back needed a 705% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$13.17 – $18.62
From 52-week high
−13.3%
vs 50-day average
−2.0%
vs 200-day average
+3.1%
Volatility (1 year)
37%
Beta vs S&P 500
0.54

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
5 up, 7 down
typical move ±8.6%
After a week
6 up, 5 down
typical move ±9.3%
After a month
7 up, 4 down
typical move ±12.9%
Results releasedNext dayS&P 500 next day5 days21 days
October 30, 2026 −6.2% −2.2% — —
August 6, 2026 +4.3% +0.5% −0.1% +5.9%
May 7, 2026 −6.2% +0.5% −2.5% −3.6%
February 26, 2026 −1.8% −1.0% +2.1% −1.1%
November 4, 2025 +9.7% −0.8% +19.1% +16.2%
July 31, 2025 +15.9% −2.0% +26.3% +32.5%
May 12, 2025 −2.2% +4.0% +0.9% +1.1%
February 27, 2025 0.0% −0.1% +3.0% +4.3%
November 7, 2024 +10.6% +1.2% +10.8% +21.4%
August 1, 2024 −6.5% −3.3% −7.0% +15.8%
February 15, 2024 −26.6% +0.2% −25.3% −36.1%
January 5, 2024 +13.4% +1.6% −5.7% −3.4%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Revenue (TTM) Aurinia Pharmaceuticals Inc.
$150M $200M $250M $300M $350M FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Revenue (TTM), FY23 Q4: $175.5M Revenue (TTM), FY24 Q1: $191.4M Revenue (TTM), FY24 Q2: $207.1M Revenue (TTM), FY24 Q3: $220.4M Revenue (TTM), FY24 Q4: $235.1M Revenue (TTM), FY25 Q1: $247.3M Revenue (TTM), FY25 Q2: $260.1M Revenue (TTM), FY25 Q3: $265.8M Revenue (TTM), FY25 Q4: $283.1M Revenue (TTM), FY26 Q1: $298.3M Revenue (TTM), FY26 Q2: $311.5M Revenue (TTM), FY26 Q3: $321.7M $321.7M

Source: SEC EDGAR filings. Retrieved November 3, 2026.

View chart data
Period Revenue (TTM)
FY23 Q4 $175.5M
FY24 Q1 $191.4M
FY24 Q2 $207.1M
FY24 Q3 $220.4M
FY24 Q4 $235.1M
FY25 Q1 $247.3M
FY25 Q2 $260.1M
FY25 Q3 $265.8M
FY25 Q4 $283.1M
FY26 Q1 $298.3M
FY26 Q2 $311.5M
FY26 Q3 $321.7M
Revenue growth, TTM YoY Aurinia Pharmaceuticals Inc.
15% 20% 25% 30% 35% 40% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Revenue growth, TTM YoY, FY23 Q4: 31.0% Revenue growth, TTM YoY, FY24 Q1: 30.4% Revenue growth, TTM YoY, FY24 Q2: 29.3% Revenue growth, TTM YoY, FY24 Q3: 38.7% Revenue growth, TTM YoY, FY24 Q4: 34.0% Revenue growth, TTM YoY, FY25 Q1: 29.2% Revenue growth, TTM YoY, FY25 Q2: 25.6% Revenue growth, TTM YoY, FY25 Q3: 20.6% Revenue growth, TTM YoY, FY25 Q4: 20.4% Revenue growth, TTM YoY, FY26 Q1: 20.6% Revenue growth, TTM YoY, FY26 Q2: 19.8% Revenue growth, TTM YoY, FY26 Q3: 21.0% 21.0%

Source: SEC EDGAR filings. Retrieved November 3, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q4 31.0%
FY24 Q1 30.4%
FY24 Q2 29.3%
FY24 Q3 38.7%
FY24 Q4 34.0%
FY25 Q1 29.2%
FY25 Q2 25.6%
FY25 Q3 20.6%
FY25 Q4 20.4%
FY26 Q1 20.6%
FY26 Q2 19.8%
FY26 Q3 21.0%
Operating margin (TTM) Aurinia Pharmaceuticals Inc.
-100% -50% 0% 50% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Operating margin (TTM), FY23 Q4: -52.2% Operating margin (TTM), FY24 Q1: -39.4% Operating margin (TTM), FY24 Q2: -29.3% Operating margin (TTM), FY24 Q3: -14.8% Operating margin (TTM), FY24 Q4: -2.0% Operating margin (TTM), FY25 Q1: 12.3% Operating margin (TTM), FY25 Q2: 20.0% Operating margin (TTM), FY25 Q3: 26.3% Operating margin (TTM), FY25 Q4: 37.1% Operating margin (TTM), FY26 Q1: 41.7% Operating margin (TTM), FY26 Q2: 48.4% Operating margin (TTM), FY26 Q3: 48.6% 48.6%

Source: SEC EDGAR filings. Retrieved November 3, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q4 -52.2%
FY24 Q1 -39.4%
FY24 Q2 -29.3%
FY24 Q3 -14.8%
FY24 Q4 -2.0%
FY25 Q1 12.3%
FY25 Q2 20.0%
FY25 Q3 26.3%
FY25 Q4 37.1%
FY26 Q1 41.7%
FY26 Q2 48.4%
FY26 Q3 48.6%
FCF margin (TTM) Aurinia Pharmaceuticals Inc.
-40% -20% 0% 20% 40% 60% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 FCF margin (TTM), FY23 Q4: -25.7% FCF margin (TTM), FY24 Q1: -18.9% FCF margin (TTM), FY24 Q2: -10.4% FCF margin (TTM), FY24 Q3: 4.1% FCF margin (TTM), FY24 Q4: 10.6% FCF margin (TTM), FY25 Q1: 18.1% FCF margin (TTM), FY25 Q2: 28.1% FCF margin (TTM), FY25 Q3: 37.9% FCF margin (TTM), FY25 Q4: 41.1% FCF margin (TTM), FY26 Q1: 49.5% FCF margin (TTM), FY26 Q2: 50.0% FCF margin (TTM), FY26 Q3: 49.0% 49.0%

Source: SEC EDGAR filings. Retrieved November 3, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q4 -25.7%
FY24 Q1 -18.9%
FY24 Q2 -10.4%
FY24 Q3 4.1%
FY24 Q4 10.6%
FY25 Q1 18.1%
FY25 Q2 28.1%
FY25 Q3 37.9%
FY25 Q4 41.1%
FY26 Q1 49.5%
FY26 Q2 50.0%
FY26 Q3 49.0%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q, 40-F. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Sept 2026
Income
Revenue 0 0 0 0 50 46 134 176 235 283 322
Gross profit — — — 0 50 45 128 161 207 250 292
EBITDA — — −55 −91 −103 −178 −109 −80 15 124 176
Operating income −25 −47 −55 −91 −104 −181 −111 −92 −5 105 156
Net income −23 −71 −53 −88 −103 −181 −108 −78 6 287 314
Diluted EPS — — −$0.63 −$0.95 −$0.87 −$1.40 −$0.76 −$0.54 $0.04 $2.07 $2.31
Growth (year on year)
Revenue — +141.6% +10.8% −31.3% +>999% −9.0% +193.9% +31.0% +34.0% +20.4% +21.0%
EBITDA — — — — — — — — — +742.7% +96.4%
Operating income — — — — — — — — — — +123.4%
Net income — — — — — — — — — +>999% +303.7%
Diluted EPS — — — — — — — — — +>999% +321.0%
Margins
Gross margin — — — 100.0% 100.0% 97.6% 95.8% 91.9% 88.0% 88.5% 90.6%
EBITDA margin — — <−999% <−999% −205.4% −390.3% −81.1% −45.6% 6.3% 43.9% 54.6%
Operating margin <−999% <−999% <−999% <−999% −208.1% −396.3% −83.2% −52.2% −2.0% 37.1% 48.6%
Net margin <−999% <−999% <−999% <−999% −204.9% −396.8% −80.7% −44.5% 2.4% 101.5% 97.7%
Free-cash-flow margin <−999% <−999% — — — — — — — — —
Cash flow
Cash from operations −19 −41 −52 −64 −70 −158 −80 −33 44 136 177
Capital spending 0 0 — — — — — — — — —
Free cash flow −19 −41 — — — — — — — — —
Stock-based pay 1 4 7 7 17 31 32 45 32 15 15
Free cash flow after stock pay −20 −45 — — — — — — — — —
Balance sheet
Cash 40 166 118 306 272 232 94 49 83 80 46
Total debt — — 0 0 0 0 0 0 0 0 0
Net debt (negative = net cash) −40 −166 −118 −306 −272 −232 −94 −49 −83 −80 −46
Diluted shares 35m 77m 85m 93m 118m 129m 142m 143m 146m 139m 136m
Returned to shareholders
Buybacks — — — — — — 0 0 40 98 75
Total returned — — — — — — 0 0 40 98 75

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Older annual columns retain the reporting standard and currency used in those filings, translated separately to USD. Current filings replace overlapping periods. Reporting changes can affect comparability; older bases are not used to fill current valuation inputs.

Financial health

3 of 3 checks passed · September 30, 2026
What it owns · $826m
Short-term assets $588mLonger-term assets $238m
What it owes, and who funded it · $826m
Short-term liabilities $96mLonger-term liabilities $72mShareholders' equity $658m
  • Short-term assets cover short-term liabilities $588m of assets due within a year against $96m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $588m short-term assets against $72m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Operating income of $156m against $4m of interest.

From Aurinia Pharmaceuticals Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

FY2026 Q3 TTM
Buybacks (TTM)
$74.9M
Returned to shareholders
47%
of free cash flow
Buybacks, last 3 fiscal years
$138M
Diluted share count
−4.1%
year over year
Total shareholder yield
3.5%
dividends 0.0% + buybacks 3.5% of market value
R&D spending
14.9%
of revenue

Competitors: side by side with peers

Closest by revenue in biotechnology
Last 12 months unless stated AUPH IOVA ARVN ADPT VCEL VIR Median
Revenue, last 12 months $322m $325m $317m $308m $306m $303m $58m
Revenue growth, last 12 months 21.0% 34.5% −15.0% 50.1% 23.0% >999% 12.7%
Revenue growth, 3-year average 26.5% — 26.1% 17.6% 19.8% −14.8% 14.3%
Revenue growth, latest quarter 13.9% 65.7% >999% 21.5% 22.5% >999% 10.2%
Gross margin 90.6% 48.4% — 75.6% 74.6% 96.1% 82.9%
Operating margin 48.6% −92.7% −5.7% −12.2% 6.0% −92.4% −187.2%
Operating margin, 3-year average 20.0% −554.7% −145.1% −66.8% 1.6% <−999% −361.6%
Net margin 97.7% −89.1% 2.9% −20.7% 7.9% −83.0% −163.5%
Cash from operations / revenue 55.1% −81.3% −65.4% −6.8% 22.7% −66.8% −162.3%
Free-cash-flow margin 49.0% −91.2% −65.9% −7.8% 20.1% −67.1% −156.7%
Free-cash-flow margin, 3-year average 30.3% −482.4% −135.2% −43.0% 5.3% <−999% −306.5%
Stock pay / revenue 4.6% 14.4% 11.6% 15.9% 12.2% 15.5% 19.2%
Change in share count −4.1% 29.6% −7.6% 4.1% 0.6% 8.2% 8.1%

Median of all 185 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Products $271M 95.9% ▲ 25.5%
License Collaboration and Royalty Revenue $11.7M 4.1% ▼ 38.2%
Geography
Region Revenue Share YoY
United States $264M 93.2% ▲ 25.6%
Japan $19.2M 6.8% ▼ 23.3%

From Aurinia Pharmaceuticals Inc.'s 10-K filed February 26, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$1.3B
Institutions reporting
281
Shares held vs prior quarter
▲ 5.5%
Positions opened / closed
44 / 24

Top buyers and sellers, Q2 2026: 149 institutions bought and 104 sold ; the biggest buyer was Goldman Sachs Group Inc (+4.2M shares) and the biggest seller Man Group PLC (−868K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Tang Capital Management LLC $221M 13.0M 16.7% ▲ 6.7%
Blackrock, Inc. $139M 8.2M 10.5% ▲ 4.4%
Goldman Sachs Group Inc $95.4M 5.6M 7.2% ▲ 292.0%
Nea Management Company, LLC $67.4M 4.0M 5.1% 0.0%
Two Sigma Investments, LP $58.8M 3.5M 4.4% ▲ 1.1%
Arrowstreet Capital, Limited Partnership $55.4M 3.3M 4.2% ▼ 0.6%
State Street Corp $43.9M 2.6M 3.3% ▲ 2.5%
Morgan Stanley $39.2M 2.3M 3.0% ▲ 3.4%
Marshall Wace, LLP $34.7M 2.0M 2.6% ▲ 9.0%
Geode Capital Management, LLC $28.9M 1.7M 2.2% ▲ 10.8%
Renaissance Technologies LLC $26.3M 1.5M 2.0% ▼ 7.0%
D. E. Shaw & Co., Inc. $23.9M 1.4M 1.8% ▼ 10.5%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Aurinia Pharmaceuticals Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $25.1M 11 trades by 1 insider, last 12 months Insider sales History → $546,373 2 trades by 1 insider · 0% under pre-set plans
Net ▲ $24.6M net buying
Insider Date Trade Shares Price Value
Robertson Stephen P. Chief Legal Officer September 10, 2026 Sell 11,939 $15.95 $190,427
Robertson Stephen P. Chief Legal Officer August 21, 2026 Sell 20,975 $16.97 $355,946
Tang Kevin Chief Executive Officer June 2, 2026 Buy 206,005 $15.28 $3.1M
Tang Kevin Chief Executive Officer June 1, 2026 Buy 99 $15.34 $1,519
Tang Kevin Chief Executive Officer June 1, 2026 Buy 343,521 $15.28 $5.2M
Tang Kevin Chief Executive Officer May 29, 2026 Buy 262,682 $15.31 $4M
Tang Kevin Chief Executive Officer May 29, 2026 Buy 2,299 $15.35 $35,290
Tang Kevin Director March 3, 2026 Buy 184,208 $14.22 $2.6M
Tang Kevin Director March 2, 2026 Buy 115,792 $14.21 $1.6M
Tang Kevin Director March 2, 2026 Buy 83,561 $14.33 $1.2M
Tang Kevin Director February 27, 2026 Buy 300,000 $13.90 $4.2M
Tang Kevin Director February 27, 2026 Buy 1,600 $14.38 $23,008

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around January 26, 2027 estimated from the company's past filing pattern, not announced

  • October 30, 2026
  • August 6, 2026
  • May 7, 2026
  • February 26, 2026
  • November 4, 2025
  • July 31, 2025

Recent SEC filings

Data status

When each part of this page on Aurinia Pharmaceuticals Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Aurinia Pharmaceuticals Inc. in brief

What does Aurinia Pharmaceuticals Inc. do?
Aurinia Pharmaceuticals Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Aurinia Pharmaceuticals Inc.'s stock ticker?
Aurinia Pharmaceuticals Inc. trades under the ticker AUPH on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Aurinia Pharmaceuticals Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Aurinia Pharmaceuticals Inc. reported revenue of $322M, 21.0% higher than a year earlier, according to its SEC filings.
What is Aurinia Pharmaceuticals Inc.'s free cash flow?
Aurinia Pharmaceuticals Inc.'s free-cash-flow margin is 49.0% of revenue over the trailing twelve months.
Who are Aurinia Pharmaceuticals Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Tang Capital Management LLC, Blackrock, Inc. and Goldman Sachs Group Inc. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Is Aurinia Pharmaceuticals Inc. buying back stock, and does it pay a dividend?
Aurinia Pharmaceuticals Inc. spent $74.9M on share repurchases over the trailing twelve months, and its diluted share count fell 4.1% over the year.
What is Aurinia Pharmaceuticals Inc.'s market cap?
On November 2, 2026, Aurinia Pharmaceuticals Inc.'s market capitalisation was about $2.2B, with a price-to-earnings ratio of 7.0 and net debt of -$45.8M. Market figures come from third-party market data and may be delayed.
Who are Aurinia Pharmaceuticals Inc.'s competitors?
In our Biotechnology peer group, the companies closest to Aurinia Pharmaceuticals Inc. are Iovance Biotherapeutics, Inc., Arvinas, Inc., Adaptive Biotechnologies Corp, Vericel Corp and Vir Biotechnology, Inc. The side-by-side comparison below sets their revenue, margins and growth against Aurinia Pharmaceuticals Inc.'s.
Are insiders buying or selling Aurinia Pharmaceuticals Inc. stock?
Over the last 12 months, Aurinia Pharmaceuticals Inc.'s directors and officers reported 11 open-market purchases and 2 sales on Form 4. The insider trading page charts every trade.
When is Aurinia Pharmaceuticals Inc.'s next earnings date?
Around January 26, 2027, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Aurinia Pharmaceuticals Inc. announces its own schedule.